BioSpace News Archive

The Honourable Ginette Petitpas Taylor, federal Minister of Health will take part in the commemoration of World AIDS Day.

Today, the Multiple Myeloma Research Foundation (MMRF) announced new discoveries driven by its landmark CoMMpass StudySM into defining myeloma subtypes, identifying novel therapeutic targets for drug discovery, and more accurately predicting high-risk disease.

The Government of Canada is committed to a fair, responsive and effective criminal justice system that protects Canadians, holds offenders to account, supports vulnerable people, and respects the Canadian Charter of Rights and Freedoms.

A daily hydroxyurea pill may finally bring some relief for young children living with the painful and deadly blood disease sickle cell anemia (SCA) in resource-challenged sub-Saharan Africa, where the disease is prevalent and health care availability is suboptimal.

Today at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, researchers will announce findings from four studies that could greatly expand access to both curative and supportive treatments for individuals living with sickle cell disease (SCD) worldwide.

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that new data from the ongoing Phase 1 studies of IMGN632 and IMGN779, next-generation CD123- and CD33-targeting ADCs

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced preclinical data presented at the 2018 American Society of Hematology (ASH) annual meeting

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 allosteric antagonist drugs to improve immune cell trafficking to treat rare diseases and cancer, today announced the presentation of additional Phase 2 clinical data demonstrating a positive safety profile and clinical activity of X4P-001 in patients with WHIM syndrome, a rare primary immunodeficiency disease.

The Prime Minister, Justin Trudeau, issued the following statement on World AIDS Day:

Bioverativ Inc., a Sanofi company, and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced the final results of ASPIRE and B-YOND, the most comprehensive long-term studies of extended half-life factor therapies in hemophilia.